Leerink Partnrs Issues Positive Estimate for LLY Earnings

Eli Lilly and Company (NYSE:LLY) – Stock analysts at Leerink Partnrs raised their Q4 2025 EPS estimates for shares of Eli Lilly and Company in a research note issued to investors on Friday, October 31st. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $7.04 per share for the quarter, up from their prior estimate of $6.85. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company’s FY2027 earnings at $38.91 EPS.

Several other brokerages have also issued reports on LLY. Leerink Partners reissued a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. JPMorgan Chase & Co. reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. HSBC raised their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, Guggenheim restated a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Trading Up 2.2%

NYSE:LLY opened at $862.96 on Monday. The firm’s fifty day moving average is $780.74 and its 200-day moving average is $771.97. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm has a market cap of $816.75 billion, a P/E ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm posted $1.18 EPS. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the first quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company in the second quarter worth about $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. raised its position in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company in the second quarter worth about $31,000. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.